# 177Lu-labeled NY108 SPECT Imaging in Patients

> **NCT05815394** · EARLY_PHASE1 · UNKNOWN · sponsor: **Affiliated Hospital of Jiangnan University** · enrollment: 10 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 177Lu-labeled NY108

## Key facts

- **NCT ID:** NCT05815394
- **Lead sponsor:** Affiliated Hospital of Jiangnan University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-03
- **Primary completion:** 2024-03-03
- **Final completion:** 2024-12-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815394, "177Lu-labeled NY108 SPECT Imaging in Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05815394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*